Health care reforms should be more focused on eliminating waste by becoming more efficient and putting patients first.

While the FDAneeds tochange to respond to innovations in cancer therapies, regulators must maintain safeguards on drug approval.

It's time for Plan C. Clinton and her allies should let the Senate vote on the von Eschenbach nomination.

While controversy has raged over the Food and Drug Administration's (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA's role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

While controversy has raged over the Food and Drug Administration’s (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA’s role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

President Obama's FDA commissioner should avoid actions that make the drug development process more costly and inefficient.

The World Health Organization's anti-counterfeit drug task force should broaden its scope to fight the scourge of substandard pharmaceuticals.

The federal government should move from a model of bureaucratic public administration to a model of entrepreneurial public management.